You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

January 5, 2026

Vietnam Issues Guidelines on Classification of Medical Devices for Procurement

On December 31, 2025, Vietnam’s Ministry of Health (MOH) issued Circular No. 57/2025/TT-BYT providing guidance on the classification of medical devices according to technical standards and quality requirements (Circular 57), applicable to procurement activities for medical devices in Vietnam.

According to the MOH, the purpose of the classification is to establish a principle-based legal framework and regulations that enable purchasers to easily identify groups of medical devices aligned with their professional requirements and financial capacity.

Some of the key stipulations of Circular 57 are outlined below.

Basis for Determining Technical Standards and Quality

Under Circular 57, the technical standards of medical devices are determined in accordance with Vietnamese laws on standards and technical regulations, through the following means:

  • Certification of conformity with standards in accordance with Vietnamese laws on standards and technical regulations;
  • Results of conformity assessment conducted by an internationally recognized conformity assessment organization or a legally established domestic or foreign conformity assessment organization operating in Vietnam; and
  • Documentation evidencing compliance provided by the medical device owner.

The quality of medical devices is determined based on whether the device has been approved for circulation by the relevant marketing authority of one or more jurisdictions.

Classification of Medical Devices

Circular 57 classifies medical devices into six groups (from Group 1 to Group 6) based on technical standards and quality.

Medical devices subject to classification must simultaneously meet technical standards and quality requirements in accordance with professional specifications and user needs, and must be lawfully marketed in Vietnam.

Medical devices manufactured in Vietnam may participate in all corresponding groups, provided they meet the technical standards required by the user and are lawfully marketed in Vietnam.

Outlook

Circular No. 57 will take effect on February 15, 2026, while the classification requirements will become effective on January 1, 2027.

Holders of medical device registration numbers are advised to proactively prepare documentation demonstrating compliance with technical standards and quality requirements to facilitate the classification process.

RELATED INSIGHTS​ 

May 14, 2015
Vietnam’s Drug Distribution PolicyUnder its WTO commitments, Vietnam agreed to allow foreign-invested entities (FIEs) to conduct distribution services (i.e., commission agent, wholesale, and retail services) for most types of products, but it specifically excluded “pharmaceutical products and drugs.” Consequently, foreign pharmaceutical producers typically establish legal presence in Vietnam by way of representative offices through which they can conduct marketing activities, and use local drug distributors to conduct sales and delivery of their products.
May 14, 2015
To ensure harmony in regulations between ASEAN countries as well as tighten the management of drug registration, the Ministry of Health (MOH) issued Circular No. 44/2014/TT-BYT dated November 25, 2014, on Registration of Drugs (Circular 44) to replace its previous Circular No. 22/2009/TT-BYT (Circular 22) dated November 24, 2009. Circular 44 took effect on January 15, 2015. Among the contents of Circular 44, there are four main points changed from Circular 22:
May 14, 2015
As a developing country with a large population, Vietnam has long viewed parallel imports as an effective antidote to the high price of innovator drugs. The parallel importation of medicines for the prevention and treatment of human diseases is permitted, and even encouraged, under Vietnamese law. Many pharmaceutical manufacturers, however, are understandably concerned that parallel importation could lead to diminished profits, thereby reducing research and development efforts, and leading to a slowdown in the innovation of new drugs.
January 7, 2015
Tilleke & Gibbins, in association with Lex Mundi, has published the latest edition of the Guide to Doing Business in Thailand. The guide provides a comprehensive overview of the legal and business environment for investors entering the Thai market. In particular, it covers topics such as the current political climate, investment incentives, financial facilities, exchange controls, import and export regulations, establishing and operating a business, labor and employment, tax, and immigration requirements.